100 related articles for article (PubMed ID: 3334664)
21. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
23. [Combined chemotherapy in metastatic breast cancer: predictive value of dose levels and performance status].
Brufman G; Sulkes A; Fuks Z; Biran S
Harefuah; 1986 Jul; 111(1-2):24-6. PubMed ID: 3781373
[No Abstract] [Full Text] [Related]
24. Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.
Carpenter JT; Smalley RV; Raney M; Vogel CL; Weiner RS
Cancer Treat Rep; 1986 Sep; 70(9):1073-9. PubMed ID: 3527407
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
26. [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Feng J; Zheng X; Dai A
Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):468-70. PubMed ID: 10920949
[TBL] [Abstract][Full Text] [Related]
27. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
28. Dose density in breast cancer: a simple message?
Lin NU; Gelman R; Winer EP
J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
[No Abstract] [Full Text] [Related]
29. [Intra-arterial infusion chemotherapy for breast cancer].
Matsumoto Y; Terakado H; Ikawa M; Hamada E; Watanabe Y; Nakasato S; Takaki S; Murata M; Miura T
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1526-8. PubMed ID: 8854797
[TBL] [Abstract][Full Text] [Related]
30. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
32. Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
Pfeiffer P; Rose C; Ejlertsen B; Andersson M; Pedersen D; Mouridsen HT
Acta Oncol; 1996; 35 Suppl 5():57. PubMed ID: 9142967
[No Abstract] [Full Text] [Related]
33. Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
Baldini E; Gardin G; Naso C; Pronzato P; Rosso R; Rubagotti A; Monzeglio C; Brema F; Pastorino G; Amadori D
Ann N Y Acad Sci; 1993 Nov; 698():418-22. PubMed ID: 8279781
[No Abstract] [Full Text] [Related]
34. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
[No Abstract] [Full Text] [Related]
35. Patients' concerns about clinical trials in Japan.
Aoki E
Lancet; 1999 Mar; 353(9157):1019-20. PubMed ID: 10459946
[No Abstract] [Full Text] [Related]
36. CAF in metastatic breast cancer: standard therapy or another effective regimen?
Hayes DF; Henderson IC
J Clin Oncol; 1987 Oct; 5(10):1497-9. PubMed ID: 3309195
[No Abstract] [Full Text] [Related]
37. Dose intensity in chemotherapy of metastatic breast cancer.
J Clin Oncol; 1985 Jun; 3(6):889-91. PubMed ID: 3891924
[No Abstract] [Full Text] [Related]
38. High-dose chemotherapy for breast cancer: we have not heard the final word.
Bearman SI
Cancer Invest; 2000; 18(5):494-7. PubMed ID: 10834035
[No Abstract] [Full Text] [Related]
39. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study.
Nagel GA; Rauschning W; Ammon A; Beyer JH; Emrich D; Holtkamp W; Kneba M; Luig H; Marschner N; Unger C
Onkologie; 1988 Dec; 11(6):289-91. PubMed ID: 3071765
[No Abstract] [Full Text] [Related]
40. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer.
Riccardi A; Giordano M; Brugnatelli S; Ucci G; Danova M; Mora O; Fava S; Ascari E
Eur J Cancer; 1995; 31A(9):1549-51. PubMed ID: 7577090
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
